Loading
Menu
Phone :
+1 (858) 366 - 8608
Address :
NovaRhythm Biosciences, Inc
9311 SE Maricamp Rd #1007
Ocala, FL 34472 USA
Email :
info@novarhythmbio.com

© 2026, NOVARHYTHM BIOSCIENCES.

News

Novarhythm Acquires license From Sanofi

FOR IMMEDIATE RELEASE

San Diego, CA — [Month] [Day], [Year] — NovaRhythm Biosciences, a biotechnology company developing next-generation therapeutics for cardiac arrhythmias, today announced the successful in-licensing of SAR-297871, a highly selective TASK-1 potassium channel inhibitor originally developed by Sanofi for the treatment of Atrial Fibrillation (AF). Under the agreement, NovaRhythm obtains exclusive global rights to progress the molecule through IND-enabling studies and Phase 1 clinical development, with a primary objective of establishing first-in-human safety and pharmacokinetics.

SAR-297871 represents one of the most advanced precision-mechanism AF drug candidates in development today. The molecule was previously supported by extensive preclinical investment by Sanofi, including medicinal chemistry, in-vivo pharmacology, and human ex-vivo cardiac tissue validation. Data generated to date demonstrate a compelling efficacy and safety profile, with atrial-selective channel targeting designed to minimize risk of ventricular proarrhythmia, a significant limitation of existing anti-arrhythmic drugs.

 

“This agreement marks a foundational milestone for NovaRhythm,” said Paul E. Miller, PhD, CEO of NovaRhythm Biosciences. “SAR-297871 offers a novel mechanism aimed at restoring healthy cardiac rhythm and rate with fewer side effects, addressing a critical gap in the treatment landscape for millions of patients with atrial fibrillation. We are proud to continue the forward trajectory of this important asset and advance it toward first-in-human studies”.

 

Atrial Fibrillation affects more than 59 million people globally, with incidence rising as populations age. Existing drug therapies remain effective for only a subset of patients and are often limited by tolerability and safety constraints. As a next-generation mechanism directly targeting the atrial-specific TASK-1 channel, SAR-297871 seeks to overcome these therapeutic limitations and deliver improved rhythm and rate control with a more favorable risk profile.

 

A spokesperson for Sanofi added: “We are pleased to see SAR-297871 advancing into its next phase of clinical development under NovaRhythm Biosciences. NovaRhythm brings deep electrophysiology expertise and a highly focused development plan — an ideal environment for unlocking the therapeutic potential we believe this compound holds for patients living with atrial fibrillation.”

 

NovaRhythm expects to complete IND-enabling work with its established development partners and is preparing for Phase 1 initiation following regulatory clearance. The company will provide ongoing updates as the program progresses.

  

About NovaRhythm Biosciences

NovaRhythm Biosciences is a cardiovascular therapeutics company advancing first-in-class treatments for cardiac arrhythmias. The company leverages human-based disease modeling, targeted ion-channel pharmacology, and rapid-cycle translational development to bring curative rhythm-restoring therapies to patients worldwide.  NovaRhythm’s lead program, SAR-297871, is positioned to be a breakthrough therapeutic for atrial fibrillation — the most common clinically significant arrhythmia.

  

About Sanofi

Sanofi is a global healthcare leader dedicated to improving access to medicine, advancing innovative research, and supporting the health and well-being of patients around the world. With a broad global footprint and deep expertise across specialty care, vaccines, immunology, and chronic disease, Sanofi continues to deliver transformative medicines to millions of patients in over 100 countries.

  

Media Contact

NovaRhythm Biosciences Investor & Media Relations Email: info@novarhythmbio.com Phone: +1 (858) 366-8608

Website: www.novarhythmbio.com

X
LinkedIn

J. Kevin Buchi

BOARD MEMBER AND M&A ADVISOR

Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. From 1991 to 2010, Mr. Buchi served as the Chief Financial Officer at Cephalon Pharmaceuticals and from 2010 to 2011 became the Chief Executive Officer to complete the $6.9 Billion acquisition of Cephalon by Teva Pharmaceutical. Subsequently, Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd from 2012 to 2013. Mr. Buchi is currently on the Board of Directors of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) and of Benitec Biopharma (NASDAQ:BNTC). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant.

Paul E. Miller, Ph.D.

BOARD MEMBER, CEO & FOUNDING PARTNER

Dr. Miller is the Founder and CEO of Consulting Life Sciences, a biotech consulting and brokerage firm he launched in 2007. From 2009 to 2023, he served as Co-Founder and Chief Corporate Development Officer of AnaBios Corporation, a company focused on advancing translational science through the use of primary human tissues in preclinical research. With over 40 years of experience in both science and business, Dr. Miller’s research background spans a wide range of fields, including cancer biology, immunology, protein secretion, gastrointestinal function, genomics, cardiology, pain and itch therapeutics. He also spent 20 years in the cultural arts industry before fully integrating his scientific knowledge with his business expertise in the biopharmaceutical sector. Throughout his career, Dr. Miller has led the development and commercialization of innovative services for preclinical contract research organizations (CROs), helping streamline drug discovery and safety testing—efforts that generated over $80 million in revenues.

Najah Abi Georges, Ph.D.

BOARD MEMBER, CSO & FOUNDING PARTNER

Dr. Abi Gerges has over 30 years of experience in cardiovascular research and 26 years in preclinical R&D. He is a seasoned leader in drug discovery. He spent 16 years at AstraZeneca and 10 years at AnaBios, where he currently serves as Senior Vice President of Research Alliances. Dr. Abi-Georges has authored more than 59 peer-reviewed publications and has been instrumental in developing several first-in-class therapies, including Tagrisso, Zeposia, Velsipity, and APD418. Known for his deep expertise in cardiovascular drug development and safety, he is widely respected across the pharmaceutical industry and regulatory agencies.

Cooley M. Pantazis, M.D.

BOARD MEMBER, CMO & FOUNDING PARTNER

Dr. Pantazis is a board-certified pathologist and has served as the Medical Director of Laboratory Services at Advent Health in Ocala, Florida, since 2015. Formerly, he was a tenured Associate Professor and Director of Surgical Pathology at the University of Kansas Medical Center. In 2005, he founded Hemacon Laboratories, a molecular hematopathology reference lab focused on diagnosing bone marrow and blood cancers. With over 40 years of experience in both medical practice and research, Dr. Pantazis has authored more than 75 peer-reviewed publications. His expertise includes animal cancer models, laboratory test development, and molecular cancer diagnostics, and he remains actively involved in research collaborations.

J. Kevin Buchi

M&A ADVISOR

Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. From 1991 to 2010, Mr. Buchi served as the Chief Financial Officer at Cephalon Pharmaceuticals and from 2010 to 2011 became the Chief Executive Officer to complete the $6.9 Billion acquisition of Cephalon by Teva Pharmaceutical. Subsequently, Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd from 2012 to 2013. Mr. Buchi is currently on the Board of Directors of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) and of Benitec Biopharma (NASDAQ:BNTC). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant.

Shashank Upadhye, J.D. LLM

IP ADVISOR

Mr. Upadhye is a partner at Upadhye Tang LLP and a nationally recognized pharmaceutical IP and FDA strategist with nearly 30 years of experience helping pharmaceutical companies maximize asset value and investor returns through integrated patent and regulatory planning. He previously served as Chief Legal/IP/FDA Counsel at Apotex, Sandoz/Novartis, and Eon Labs, where he guided numerous drug products from development through approval and commercialization, bringing deep operational and executive-level insight. Shashank specializes in designing robust patent portfolios, exclusivity strategies, and FDA regulatory pathways that enhance competitive positioning, extend franchise life, and unlock long-term enterprise value. He is the author of the leading treatise Generic Pharmaceutical Patent and FDA Law and is widely recognized as a trusted advisor to pharmaceutical companies, executives, and investors on high-stakes IP and regulatory strategy.

Peter R. Kowey, M.D.

FDA & REGULATORY ADVISOR

Dr. Kowey is a leading American cardiologist and medical researcher. He serves as Professor of Medicine and Clinical Pharmacology at Jefferson Medical College of Thomas Jefferson University and holds the William Wikoff Smith Chair in Cardiovascular Research at the Lankenau Institute for Medical Research. A recognized expert in cardiac rhythm disorders, Dr. Kowey has authored or co-authored over 400 scientific papers and received more than 150 research grants. He has played key roles in numerous clinical trials and co-edited three major textbooks on cardiac arrhythmias. Dr.Kowey is a fellow of multiple prestigious organizations, including the American Heart Association and the American College of Cardiology. He also serves on the editorial boards of Heart Rhythm Journal and the Journal of Cardiovascular Electrophysiology, and reviews manuscripts for 25 scientific journals. He has consulted for over 60 international pharmaceutical companies, chaired multiple data and safety monitoring boards, and served as an advisor to the U.S. Food and Drug Administration.

Cooley M. Pantazis, M.D.

CHIEF MEDICAL OFFICER & FOUNDING PARTNER

Dr. Pantazis is a board-certified pathologist and has served as the Medical Director of Laboratory Services at Advent Health in Ocala, Florida, since 2015. Formerly, he was a tenured Associate Professor and Director of Surgical Pathology at the University of Kansas Medical Center. In 2005, he founded Hemacon Laboratories, a molecular hematopathology reference lab focused on diagnosing bone marrow and blood cancers. With over 40 years of experience in both medical practice and research, Dr. Pantazis has authored more than 75 peer-reviewed publications. His expertise includes animal cancer models, laboratory test development, and molecular cancer diagnostics, and he remains actively involved in research collaborations.

Najah Abi Georges, Ph.D.

CHIEF SCIENTIFIC OFFICER & FOUNDING PARTNER

Dr. Abi Gerges has over 30 years of experience in cardiovascular research and 26 years in preclinical R&D. He is a seasoned leader in drug discovery. He spent 16 years at AstraZeneca and 10 years at AnaBios, where he currently serves as Senior Vice President of Research Alliances. Dr. Abi-Georges has authored more than 59 peer-reviewed publications and has been instrumental in developing several first-in-class therapies, including Tagrisso, Zeposia, Velsipity, and APD418. Known for his deep expertise in cardiovascular drug development and safety, he is widely respected across the pharmaceutical industry and regulatory agencies.

Paul E. Miller, Ph.D.

CHIEF EXECUTIVE OFFICER & FOUNDING PARTNER

Dr. Miller is the Founder and CEO of Consulting Life Sciences, a biotech consulting and brokerage firm he launched in 2007. From 2009 to 2023, he served as Co-Founder and Chief Corporate Development Officer of AnaBios Corporation, a company focused on advancing translational science through the use of primary human tissues in preclinical research. With over 40 years of experience in both science and business, Dr. Miller’s research background spans a wide range of fields, including cancer biology, immunology, protein secretion, gastrointestinal function, genomics, cardiology, pain and itch therapeutics. He also spent 20 years in the cultural arts industry before fully integrating his scientific knowledge with his business expertise in the biopharmaceutical sector. Throughout his career, Dr. Miller has led the development and commercialization of innovative services for preclinical contract research organizations (CROs), helping streamline drug discovery and safety testing—efforts that generated over $80 million in revenues.